1. Scrip
  2. >>Business

Abivax Advances Again On Funding Front

Plus Plans In Place For NASDAQ Submission

 
• By Kevin Grogan

The French biotech has been making steady progress in raising the funds needed to advance obefazimod and this week has seen new equity backers Kreos, Claret and Heights come onboard.

Paris
Paris is home to Abivax • Source: Shutterstock

Having openly declared its desire to pursue a listing in the US, Abivax SA has also secured access to a significant injection of funds to finance the last-stage program of obefazimod, its closely-watched investigational treatment for ulcerative colitis (UC).

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Scrip for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required
Start Free Trial

Already a subscriber?

More from Financing

More from Business

In Brief: Merck To Invest $1bn In New US Biologics Production

 
• By Sushmita Panda

Merck is investing $ 1bn in a Delaware facility to produce Keytruda and expand biologics manufacturing amid US tariff concerns.

Can European Biotech Survive And Thrive In Era Of Instability?

 
• By Andrew McConaghie

Europe's biopharma sector could suffer if the Trump administration incentivizes US investment but VC leaders believe the region can still thrive and potentially capitalize on instability elsewhere.

GSK Chief Optimistic About BD Despite Volatile Environment

 
• By Kevin Grogan

Emma Walmsley tells Scrip that the "biotech market is under a certain degree of pressure," so reasonably priced deals are available.